Tag: MSI-H

US approves Keytruda for MSI-H tumours

by Selina McKee | May 24, 2017 | News | 0

The US Food and Drug Administration has cleared use of Merck & Co’s immunotherapy Keytruda to treat cancer patients identified as having a biomarker called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Speedy review for BMS’ Opdivo in colorectal cancers

by Selina McKee | Apr 5, 2017 | News | 0

The US Food and Drug Administration will undertake a priority review of Bristol-Myers Squibb’s immunotherapy Opdivo as a treatment for patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC).